


PBRM1-BD2-IN-8

| | | | |
|--------------------|--|-------|----------|
| Cat. No.: | HY-151538 | | |
| CAS No.: | 2819989-75-6 | | |
| Molecular Formula: | C ₁₅ H ₁₃ BrN ₂ O | | |
| Molecular Weight: | 317.18 | | |
| Target: | Epigenetic Reader Domain | | |
| Pathway: | Epigenetics | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



BIOLOGICAL ACTIVITY

| | | | |
|---------------------------|---|--|--|
| Description | PBRM1-BD2-IN-8 (compound 34) is a potent PBRM1 Bromodomain inhibitor (PBRM1-BD2 K _d =4.4 μM, PBRM1-BD2 IC ₅₀ =0.16 μM; PBRM1-BD5 K _d =25 μM). PBRM1-BD2-IN-8 shows anti-cancer activity ^[1] . | | |
| IC ₅₀ & Target | IC ₅₀ : 0.16 μM (PBRM1-BD2) ^[1] | | |
| In Vitro | PBRM1-BD2-IN-8 (0-100 μM; 48 h) inhibits the growth of PBRM1-dependent prostate cancer cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[1] | | |
| | Cell Line: | LNCaP cells | |
| | Concentration: | 0-100 μM | |
| | Incubation Time: | 48 hours | |
| | Result: | Inhibited the growth of LNCaP cells with IC ₅₀ value of about 9 μM. | |

REFERENCES

[1]. Shishodia S, et al. Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening. J Med Chem. 2022 Oct 13.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA